Ohio State startup acquired for $8.7B
The company develops gene therapies using research that originated at Nationwide Children’s Hospital and Ohio State. AveXis announced the acquisition agreement with Novartis on Monday. The university could realize about $2.7 million from its stake in AveXis based on current and recently sold holdings.
AveXis is focused on treatments for rare and life-threatening neurological diseases, including a form of spinal muscular atrophy that is the leading genetic cause of infant mortality. Completion of the transaction is expected in mid-2018.
Ohio State supports the development and commercialization of discoveries through its Technology Commercialization Office. In all, there are currently 74 startup companies have been created from Ohio State research.